Chimeric Antigen Receptor Immunotherapy for Infectious Diseases: Current Advances and Future Perspectives

Area of Science:

• Immunology
• Cell Therapy
• Infectious Diseases

Background:

• Chimeric antigen receptor (CAR)-T cell immunotherapy has transformed B-cell malignancy treatment.
• Emerging evidence suggests CAR-engineered cells (T cells, NK cells, macrophages) show potential in autoimmune disorders and solid tumors.
• The rise of chronic infections, multidrug-resistant pathogens, and infections in immunocompromised individuals necessitates novel therapeutic strategies.

Purpose of the Study:

• To review current clinical and preclinical data on CAR cell products for infectious diseases.
• To highlight the potential of CAR cell therapy in managing chronic infections and infectious complications.
• To underscore the need for personalized therapies in infectious disease management.

Main Methods:

• Literature review of ongoing clinical and preclinical studies.
• Analysis of data on CAR cell applications in infectious diseases.
• Focus on human immunodeficiency virus (HIV) infection and other preclinical models.

Main Results:

• CAR immunotherapy is primarily studied for HIV infection in clinical settings.
• Data for other infections predominantly come from preclinical in vitro and in vivo models.
• CAR cell therapy is being developed for the management of chronic infections.

Conclusions:

• CAR cell therapy holds potential for treating chronic infections and infectious complications.
• Further research and clinical trials are needed to establish efficacy and safety for various infections.
• CAR cell therapy represents a promising avenue for personalized medicine in infectious disease management.